Clinical Data's vilazodone succeeds in second Phase III trial
This article was originally published in Scrip
Executive Summary
Clinical Data Inc has announced positive top-line data from its second pivotal Phase III trial of its novel antidepressant vilazodone in patients with major depressive disorder (MDD).